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=======================================================

In retrospect, high‐throughput screening (HTS) with microtiter plates has been the major tool used in pharmaceutical industry to explore the chemical diversity space to find lead compounds and pharmacophores for specific biological targets (including those arising from genomic and proteomic research). To reduce the screening cost and increasing screening efficiency, many new tools have emerged in HTS application, and chemical microarray is one of the new technologies showing great promise. The earlier development of chemical microarray followed DNA array technology by immobilizing chemical compounds on the surface of microarray to probe the biological target with binding assay ([1](#b1){ref-type="ref"}). However, given \>10^40^ potential low molecular weight chemical compounds available in theory ([2](#b2){ref-type="ref"}), many difficulties will be encountered with immobilization, drying or caging compound with other material. To avoid these problems, we have developed a novel solution‐phase chemical compound microarray, DiscoveryDot^TM^ (Reaction Biology Corporation, Malvern, PA, USA). In this format, each compound is individually arrayed on glass surface with reaction buffer plus low concentration of glycerol, and activated with biological targets by delivering analytes with an aerosol deposition technology ([Figure 1](#f1){ref-type="fig"}) ([3](#b3){ref-type="ref"}, [4](#b4){ref-type="ref"}, [5](#b5){ref-type="ref"}). As this technology exactly mimics the conventional well‐based screenings, chemical compounds are always in reaction solutions; therefore, any organic compound library can be manufactured. With different detection methods, this microarray can be used for assaying enzymatic reactions, protein--protein interactions, antigen--antibody screening and potentially receptor bindings.

![**The execution procedure of DiscoveryDot** ^**TM**^ **platform.** A) Compounds are arrayed as solution‐phase individual reaction centers. B) Microarray is activated by a fine aerosol mist of analytes. C) Reactions were detected and analyzed with imaging instruments.](CBDD-67-87-g001){#f1}

Currently 6600 individual nanoliter reactions are screened on one regular 1′′ × 3′′ microarray chip, which is equal to 17 of 384‐well plates. A single printing run can rapidly create hundred sets of the library; piezo‐aerosol only need microliters analytes to activate all nanoliter reactions at the same time, this technology could reduce the HTS cost over 90%. For example, a 66 000 compound screen required only \$10 of Factor Xa ([4](#b4){ref-type="ref"}). In conventional kinases HTS and profiling, peptide substrates are often used instead of native protein substrates because of the high cost of generating pure protein substrates. However, this practice creates large number of inhibitors which are target unspecific. As only microgram of native proteins is needed for DiscoveryDot^TM^‐based screening, kinase HTS and profiling could be performed with native protein substrate at very low cost ([5](#b5){ref-type="ref"}). For example, less than ¢0.1 per reaction of native protein substrate, dephosphorylated myelin basic protein, is needed for screening p38*α* MAP kinase against LOPAC library ([Figure 2](#f2){ref-type="fig"}). More recently, DiscoveryDot^TM^ technology has been successfully used in the discovery of a cathepsin L inhibitor, MDL28170, which prevented severe acute respiratory syndrome (SARS) virus from entering targeted cells ([6](#b6){ref-type="ref"}). This study opened a new target class for developing drugs that could be therapeutically very useful to against the SARS virus.

![**Serine/threonine kinases p38** *α* **screening against LOPAC library**. Dephosphorylated myelin basic protein was used as substrate to coat microarray, and LOPAC library (Sigma, St Louis, MO, USA) was then microarrayed and activated by p38*α*. Compound, SB202190, a potent and cell permeable inhibitor of p38 MAP kinase stood out as strong inhibitor during screening (see arrow at subarray\#9, column 1 and row 18), which was then confirmed by well‐based reaction.](CBDD-67-87-g002){#f2}
